Free Trial

Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Sicart Associates LLC

Illumina logo with Medical background

Sicart Associates LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 60,685 shares of the life sciences company's stock after selling 3,177 shares during the quarter. Illumina makes up approximately 2.9% of Sicart Associates LLC's portfolio, making the stock its 11th biggest position. Sicart Associates LLC's holdings in Illumina were worth $8,109,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares in the last quarter. TD Private Client Wealth LLC increased its stake in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after purchasing an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina during the 2nd quarter worth approximately $61,000. Finally, Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after buying an additional 212 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research reports. Barclays boosted their price target on shares of Illumina from $135.00 to $145.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. Hsbc Global Res raised Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Citigroup lowered Illumina from a "buy" rating to a "neutral" rating and cut their price target for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. TD Cowen increased their price objective on Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Finally, UBS Group lifted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $165.63.

Check Out Our Latest Analysis on ILMN

Illumina Price Performance

Shares of ILMN traded down $0.70 during trading hours on Friday, reaching $136.67. The company had a trading volume of 1,247,185 shares, compared to its average volume of 1,687,617. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The firm has a 50 day simple moving average of $139.88 and a 200-day simple moving average of $133.16. The company has a market capitalization of $21.68 billion, a price-to-earnings ratio of -13.72 and a beta of 1.11.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the company posted $0.33 earnings per share. Research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

About Illumina

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Articles

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Should You Invest $1,000 in Illumina Right Now?

Before you consider Illumina, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.

While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines